Mersana Therapeutics (MRSN) IPO Opens Modestly Lower

Today's IPO for Mersana Therapeutics (NASDAQ: MRSN) opened for trading at $14.25 after pricing 5,000,000 shares of common stock at a public offering price of $15.00 per share.

J.P. Morgan, Cowen and Leerink Partners acted as book-running managers for the offering. Wedbush PacGrow acted as co-manager for the offering.

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary ADC platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients. Our lead product candidate, XMT-1522, is in Phase I clinical trials. We expect that our second product candidate, XMT-1536, will be entering clinical trials in early 2018. In addition, our partners are advancing their pipeline of ADCs using our platform.

You May Also Be Interested In

• Holtec Nuclear Corporation files for initial public offering
• Men’s Wearhouse owner Tailored Brands, bankrupt in 2020, files for IPO
• SK Hynix eyes blockbuster US debut with $149 ADR target, Bloomberg reports